Top Markets
Coin of the day
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
株式のランク #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
株価
$0.1559364
最終同期: 2026-09-18
時価総額
$195.17K
変化(1日)
6.60%
変化(1年)
-30.91%
GB
取引 Fusion Antibodies plc (FAB)

カテゴリー

Fusion Antibodies plc(FAB)のP/B比率
September 2026 時点のP/B比率 TTM: 14.42
Fusion Antibodies plc の最新の財務報告および株価によると、現在のP/B比率(TTM)は 14.42 です。2024 年末時点でのP/B比率は 1.19 でした。
Fusion Antibodies plc の P/B 比率の履歴(2013 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
2026 (TTM) 14.42 63.73%
2025 8.81 638.88%
2024 1.19 -86.62%
2023 8.92 111.06%
2022 4.23 -49.81%
2021 8.42 93.06%
2020 4.36 270.89%
2019 1.18 -54.53%
2018 2.59 -83.83%
2017 15.99 -14.59%
2016 18.73 -88.38%
2015 161.16 -102.17%
2014 -7.41K -918.70%
2013 905.56 0.00%
同業他社のP/B比率
企業 P/B比率 P/B比率の差
6.5144 -54.84%
US
7.3983 -48.71%
NL
8.5918 -40.43%
US
3.9974 -72.29%
AU
- -
CH